摘要
Access Directors are dedicated to co-developing innovative and winning market access strategies, optimizing the payer value proposition and access-relevant evidence packages for assets, in partnership with the CLS and crossfunctional teams.
They develop and implement transformative access solutions serving strategic disease areas (DAs) and maximizing IM assets, with focus on our priority geographic markets (CN, DE, JP), major HTA archetypes (e.g., UK/CAN) and
Budget Impact archetypes (e.g., Italy/Spain) needs and feasibility.
Access Directors,
• Represent access with internal partners and external stakeholders. Internally, drive vision, inspire and provide leadership throughout the Access community (International, Regions, Countries) and with key partners (CPS/International, Development, Biomedical Research, Operations, S&G, Regions and Countries). Externally, represent Novartis in appropriate fora and organizations to drive the Novartis strategic access agenda.
• With International TA, develop and deliver all aspects of access strategy and execution for compounds/brands across the R-D-C continuum.
• Collaborate and partner with TAs, Medical Affairs, Development and Biomedical Research to enhance the value proposition, access strategy and access-relevant evidence packages. Ensure access landscaping and payer
evidence requirements are built into TPPs, clinical development plans, integrated product strategies, indication sequencing/asset maximization.
• Enable asset strategy to translate science into payer and HCS value propositions and solutions, securing access, affordability, and contribute to wide scale patient access and efficiencies at scale.
• With CLS and Pricing team, (co-)create the international pricing strategy and guidance.
• With CLS, generate payer negotiation strategy, upskill and prepare countries for their payer negotiations.
• With CLS, create innovative patient access and contracting approaches, Managed Entry Agreements (MEAs) and Patient Support Programs (PSPs) as required, to improve patient outcomes and support healthcare system
affordability.
• Ensure the appropriate and timely access inputs into IEPs, IPS, asset maximization incl. indication sequencing.
• Create collaborative partnerships internally and externally to break down silos, partner across the value chain and shape the future of healthcare and markets.
• Manage resource requirements to address asset/DA priorities.